NUCYNTA (tapentadol hydrochloride) by Humanwell Pharmaceutical is centrally-acting synthetic analgesic. First approved in 2012.
Drug data last refreshed 21h ago · AI intelligence enriched 1w ago
NUCYNTA (tapentadol hydrochloride) is a centrally-acting synthetic analgesic approved as an oral solution that combines mu-opioid receptor agonism with norepinephrine reuptake inhibition for pain management. The dual mechanism allows analgesia through both opioid and noradrenergic pathways, though the clinical relevance of each component remains incompletely characterized. It is used for moderate to severe pain management in patients requiring opioid-level analgesia.
Post-LOE positioning indicates brand consolidation and defensive strategy; expect smaller team focused on retention and lifecycle management rather than growth initiatives.
centrally-acting synthetic analgesic. The exact mechanism of action is unknown. Although the clinical relevance is unclear, preclinical studies have shown that tapentadol is a mu-opioid receptor (MOR) agonist and a norepinephrine reuptake inhibitor (NRI). Analgesia in animal models is derived from…
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
A Safety and Effectiveness Study of Immediate Release Tapentadol Hydrochloride Among Filipino Patients With Moderate to Severe Acute Non-Cancer Pain
A Safety and Effectiveness Study of Prolonged Release Tapentadol Hydrochloride Among Filipino Patients With Moderate to Severe Chronic Non-Cancer Pain
NUCYNTA (Tapentadol Immediate Release) Versus Oxycodone Immediate Release in the Treatment of Acute Low Back Pain
Worked on NUCYNTA at Humanwell Pharmaceutical? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Patent cliff in less than a year — expect lifecycle management and generic defense hiring
NUCYNTA offers limited career growth opportunities given its post-LOE status and imminent 2026 generic entry; roles focus on defensive market management and stakeholder relations rather than expansion. Professionals joining this brand should expect emphasis on efficiency, pricing strategy, and managed decline rather than product innovation or team expansion.
Upgrade to Pro to access patent cliff timelines and LOE dates and other premium pharma intelligence.
Upgrade to Pro — $25/mo